<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Both acid and duodenal contents are thought to be responsible for the mucosal damage in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, a condition often treated medically </plain></SENT>
<SENT sid="1" pm="."><plain>However, little is known about the effect of <z:chebi fb="14" ids="7772">omeprazole</z:chebi> on <z:e sem="disease" ids="C0013299" disease_type="Disease or Syndrome" abbrv="">duodenogastric reflux</z:e> (DGR) and duodenogastro-<z:e sem="disease" ids="C0017168,C0559234" disease_type="Disease or Syndrome;Finding" abbrv="">oesophageal reflux</z:e> (DGOR) </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS: To study the effect of <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg twice daily on DGR and DGOR, using the technique of ambulatory <z:chebi fb="0" ids="16990">bilirubin</z:chebi> monitoring </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Twenty three patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> underwent manometry followed by 24 hour oesophageal and gastric pH monitoring </plain></SENT>
<SENT sid="4" pm="."><plain>In conjunction with pH monitoring, 11 patients (group 1) underwent oesophageal <z:chebi fb="0" ids="16990">bilirubin</z:chebi> monitoring and 12 patients (group 2) underwent gastric <z:chebi fb="0" ids="16990">bilirubin</z:chebi> monitoring, both before and during treatment with <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg twice daily </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In both groups there was a significant reduction in oesophageal acid (pH&lt;4) reflux (p&lt;0.005) and a significant increase in the time gastric pH was above 4 (p&lt;0.005) </plain></SENT>
<SENT sid="6" pm="."><plain>In group 1, median total oesophageal <z:chebi fb="0" ids="16990">bilirubin</z:chebi> exposure was significantly reduced from 28.9% to 2.4% (p&lt;0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>In group 2, median total gastric <z:chebi fb="0" ids="16990">bilirubin</z:chebi> exposure was significantly reduced from 24.9% to 7.2% (p&lt;0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Treatment of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> with <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg twice daily results in a notable reduction in the exposure of the oesophagus to both acid and duodenal contents </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, delivery of duodenal contents to the upper gastric body is reduced </plain></SENT>
</text></document>